MedTrace Logo

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

NCT00123851 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2009-04-28

No results posted yet for this study

Summary

This trial is designed to investigate the safety, tolerability and the effectiveness when OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer.

Conditions

Interventions

DRUG

Tarceva (OSI-774)

DRUG

Capecitabine

DRUG

Oxaliplatin

Sponsors & Collaborators

Principal Investigators

  • Jeffrey A. Meyerhardt, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00123851 on ClinicalTrials.gov